La voie biochimique de la phosphatidylinositol-3-kinase (PI3K) est l'une des voies les plus
souvent dérégulées dans le cancer et la cible de nombreux nouveaux médicaments. Le …

The following proposal describes a modular machine learning approach that detects
malfunctioning genes and pathways in cancer using the transcriptome of cancer patients …

Systematic tumor genomic profiling has the following two overarching objectives in clinical
oncology: the matching of a cancer drug to a specific tumor genetic context and the …

Alterations of PI-3 kinases (PIK3) in cancer represent a novel drug-targetable biomarker for
multiple solid tumors. One such drug, alpelisib, in combination with fulvestrant, has been …

Abstract Context: The PI3K/AKT/PTEN pathway is frequently aberrantly activated in breast
cancer (BC) and involved in resistance to hormonal therapy. Multiple drugs targeting this …

Genotyping of patient tumors has been rapidly incorporated into both clinical trials and
clinical practice over the last several years, with the goal of advancing personalized or …

Most academic precision oncology programs have been designed to facilitate enrollment of
patients in early clinical trials with matched targeted agents. Over the last decade, major …

Background Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K),
encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of …

Although many inhibitors of the PI3K signaling pathway are currently undergoing clinical
development, knowledge of the molecular determinants of response to these inhibitors is …

Abstract The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human
cancers, and several agents targeting this pathway including PI3K/Akt/mammalian target of …